Mike Thompson

Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease

Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared on X:

“S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease to direct Therapy Duration (DRAMMATIC) – Amrita Krishnan, Hoering, Phari, Sexton, Robert Z. Orlowski.

ASH20 Abstract 1515

1515 Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton, Robert Z. Orlowski

Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease

Amrita Krishnan Antje Hoering cancer Mike Thompson Myeloma OncoDaily Oncology Parameswaran Hari Rachael Sexton Robert Z. Orlowski